The Motley Fool's Kristine Harjes and Todd Campbell discuss what trial failure, commercial failure, and patent expiration at Celldex, MannKind, and PDL BioPharma, respectively, teaches investors about managing risk in the industry.

The Motley Fool's Kristine Harjes and Todd Campbell discuss what trial failure, commercial failure, and patent expiration at Celldex, MannKind, and PDL BioPharma, respectively, teaches investors about managing risk in the industry.

The Motley Fool's Kristine Harjes and Todd Campbell&nbsp;discuss what&nbsp;trial failure, commercial failure, and patent expiration at Celldex, MannKind, and PDL BioPharma, respectively, teaches&nbsp;investors about managing&nbsp;risk in the industry.

Healthcare: 3 Big Risks Facing Biotech Stocks

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Healthcare: 3 Big Risks Facing Biotech Stocks

Sign up to save your podcasts

Healthcare: 3 Big Risks Facing Biotech Stocks

Healthcare: 3 Big Risks Facing Biotech Stocks

More shows like Industry Focus

Motley Fool Hidden Gems Investing

Motley Fool Answers

Rule Breaker Investing

MarketFoolery